FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963882854> ?p ?o ?g. }

• W1963882854 endingPage "29" @default.
• W1963882854 startingPage "22" @default.
• W1963882854 abstract "Background The EUROpean Ewing tumour Working Initiative of National Groups 1999 (EURO-E.W.I.N.G. 99) protocol prescribes six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) as intensive induction chemotherapy for Ewing tumors (ET). Granulocyte-colony stimulating factor (G-CSF) is recommended. Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed. Procedure Safety data from 4,746 courses of VIDE in 851 patients less than 50 years with ET were collected using a checklist and evaluated using descriptive statistics with sub-groups including gender, age, and tumor volume, analyzed by Wilcoxon and Kruskal–Wallis tests. Results Myelosuppression and infections were the major AR but with appropriate supportive therapy targeted dose intensity was maintained. Five VIDE-related deaths with three due to sepsis were reported. Renal and cardiac toxicity were reflected by glomerular filtration rate (GFR) <39 ml/min/1.73m2 in 0.1%, tubular phosphate reabsorption ≤0.80 in 1.9%, and left ventricular shortening fracture <28% in 2.5% VIDE courses. Statistically significant gender-associated AR concerning hemoglobin and platelets were observed with females > males as were age-associated AR concerning hemoglobin, WBC, platelets, stomatitis, and vomiting with AR decreasing with age, that is, children > adolescents > adults. No association of AR to tumor volume was found. In VIDE courses with and without G-CSF, neutropenia-related fever in 60.8% and 65.8%, and infection in 54.7% and 61.0% courses, respectively, were recorded. Conclusions AR under VIDE remained within the expected range. Some AR, for example, hematotoxicity were significantly influenced by age and gender but not by tumor volume. G-CSF did not significantly influence neutropenia-related fever and infection. Solicited safety collection with checklists adequately reflects the burden per course. Pediatr Blood Cancer © 2006 Wiley-Liss, Inc." @default.
• W1963882854 created "2016-06-24" @default.
• W1963882854 creator A5001373279 @default.
• W1963882854 creator A5006127629 @default.
• W1963882854 creator A5022943207 @default.
• W1963882854 creator A5024265201 @default.
• W1963882854 creator A5027448217 @default.
• W1963882854 creator A5052878064 @default.
• W1963882854 creator A5056568252 @default.
• W1963882854 creator A5067218613 @default.
• W1963882854 creator A5069618754 @default.
• W1963882854 creator A5077857401 @default.
• W1963882854 date "2006-01-01" @default.
• W1963882854 modified "2023-10-17" @default.
• W1963882854 title "Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial" @default.
• W1963882854 cites W1496635226 @default.
• W1963882854 cites W163236235 @default.
• W1963882854 cites W1797236870 @default.
• W1963882854 cites W1855359775 @default.
• W1963882854 cites W1860006956 @default.
• W1963882854 cites W1968626722 @default.
• W1963882854 cites W1974260639 @default.
• W1963882854 cites W1979993991 @default.
• W1963882854 cites W1980751301 @default.
• W1963882854 cites W2034481315 @default.
• W1963882854 cites W2036296711 @default.
• W1963882854 cites W2051912517 @default.
• W1963882854 cites W2072315137 @default.
• W1963882854 cites W2100055648 @default.
• W1963882854 cites W2103353598 @default.
• W1963882854 cites W2103460784 @default.
• W1963882854 cites W2115232506 @default.
• W1963882854 cites W2125101586 @default.
• W1963882854 cites W2136973158 @default.
• W1963882854 cites W2163553551 @default.
• W1963882854 cites W2419781992 @default.
• W1963882854 cites W2765828539 @default.
• W1963882854 cites W4240411593 @default.
• W1963882854 doi "https://doi.org/10.1002/pbc.20820" @default.
• W1963882854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16572419" @default.
• W1963882854 hasPublicationYear "2006" @default.
• W1963882854 type Work @default.
• W1963882854 sameAs 1963882854 @default.
• W1963882854 citedByCount "222" @default.
• W1963882854 countsByYear W19638828542012 @default.
• W1963882854 countsByYear W19638828542013 @default.
• W1963882854 countsByYear W19638828542014 @default.
• W1963882854 countsByYear W19638828542015 @default.
• W1963882854 countsByYear W19638828542016 @default.
• W1963882854 countsByYear W19638828542017 @default.
• W1963882854 countsByYear W19638828542018 @default.
• W1963882854 countsByYear W19638828542019 @default.
• W1963882854 countsByYear W19638828542020 @default.
• W1963882854 countsByYear W19638828542021 @default.
• W1963882854 countsByYear W19638828542022 @default.
• W1963882854 countsByYear W19638828542023 @default.
• W1963882854 crossrefType "journal-article" @default.
• W1963882854 hasAuthorship W1963882854A5001373279 @default.
• W1963882854 hasAuthorship W1963882854A5006127629 @default.
• W1963882854 hasAuthorship W1963882854A5022943207 @default.
• W1963882854 hasAuthorship W1963882854A5024265201 @default.
• W1963882854 hasAuthorship W1963882854A5027448217 @default.
• W1963882854 hasAuthorship W1963882854A5052878064 @default.
• W1963882854 hasAuthorship W1963882854A5056568252 @default.
• W1963882854 hasAuthorship W1963882854A5067218613 @default.
• W1963882854 hasAuthorship W1963882854A5069618754 @default.
• W1963882854 hasAuthorship W1963882854A5077857401 @default.
• W1963882854 hasConcept C126322002 @default.
• W1963882854 hasConcept C141071460 @default.
• W1963882854 hasConcept C2776694085 @default.
• W1963882854 hasConcept C2776755627 @default.
• W1963882854 hasConcept C2777063308 @default.
• W1963882854 hasConcept C2777506904 @default.
• W1963882854 hasConcept C2778119113 @default.
• W1963882854 hasConcept C2779429289 @default.
• W1963882854 hasConcept C71924100 @default.
• W1963882854 hasConceptScore W1963882854C126322002 @default.
• W1963882854 hasConceptScore W1963882854C141071460 @default.
• W1963882854 hasConceptScore W1963882854C2776694085 @default.
• W1963882854 hasConceptScore W1963882854C2776755627 @default.
• W1963882854 hasConceptScore W1963882854C2777063308 @default.
• W1963882854 hasConceptScore W1963882854C2777506904 @default.
• W1963882854 hasConceptScore W1963882854C2778119113 @default.
• W1963882854 hasConceptScore W1963882854C2779429289 @default.
• W1963882854 hasConceptScore W1963882854C71924100 @default.
• W1963882854 hasIssue "1" @default.
• W1963882854 hasLocation W19638828541 @default.
• W1963882854 hasLocation W19638828542 @default.
• W1963882854 hasOpenAccess W1963882854 @default.
• W1963882854 hasPrimaryLocation W19638828541 @default.
• W1963882854 hasRelatedWork W1974421033 @default.
• W1963882854 hasRelatedWork W2006516489 @default.
• W1963882854 hasRelatedWork W2018507611 @default.
• W1963882854 hasRelatedWork W2047216338 @default.
• W1963882854 hasRelatedWork W2054697909 @default.
• W1963882854 hasRelatedWork W2146204018 @default.
• W1963882854 hasRelatedWork W2270672625 @default.
• W1963882854 hasRelatedWork W2428528889 @default.

• next